C.R. Bard, Inc. (BCR) Holdings Trimmed by Sei Investments Co.
Sei Investments Co. reduced its holdings in shares of C.R. Bard, Inc. (NYSE:BCR) by 22.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,591 shares of the medical instruments supplier’s stock after selling 7,484 shares during the period. Sei Investments Co.’s holdings in C.R. Bard were worth $8,185,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of the business. Alps Advisors Inc. grew its holdings in C.R. Bard by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 1,921 shares of the medical instruments supplier’s stock worth $607,000 after acquiring an additional 5 shares during the period. KCM Investment Advisors LLC grew its stake in shares of C.R. Bard by 0.5% in the 2nd quarter. KCM Investment Advisors LLC now owns 2,187 shares of the medical instruments supplier’s stock valued at $691,000 after buying an additional 10 shares during the period. Parallel Advisors LLC grew its stake in shares of C.R. Bard by 2.8% in the 2nd quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock valued at $164,000 after buying an additional 14 shares during the period. First Merchants Corp grew its stake in shares of C.R. Bard by 0.6% in the 2nd quarter. First Merchants Corp now owns 5,135 shares of the medical instruments supplier’s stock valued at $1,623,000 after buying an additional 32 shares during the period. Finally, Advisor Partners LLC grew its stake in shares of C.R. Bard by 4.9% in the 2nd quarter. Advisor Partners LLC now owns 1,360 shares of the medical instruments supplier’s stock valued at $430,000 after buying an additional 63 shares during the period. Hedge funds and other institutional investors own 80.31% of the company’s stock.
Several brokerages have recently commented on BCR. Barclays PLC raised their target price on C.R. Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research note on Monday, November 6th. Cowen and Company restated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research note on Friday, November 3rd. Needham & Company LLC restated a “hold” rating on shares of C.R. Bard in a research note on Thursday, October 26th. Jefferies Group LLC restated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research note on Thursday, September 14th. Finally, BidaskClub downgraded C.R. Bard from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $303.50.
C.R. Bard, Inc. (BCR) opened at $336.66 on Wednesday. The stock has a market capitalization of $24,294.30, a PE ratio of 28.78, a price-to-earnings-growth ratio of 2.55 and a beta of 0.53. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72. C.R. Bard, Inc. has a 12 month low of $206.26 and a 12 month high of $336.98.
C.R. Bard (NYSE:BCR) last released its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.06. The business had revenue of $989.80 million during the quarter, compared to the consensus estimate of $990.64 million. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. The company’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.64 EPS. equities research analysts expect that C.R. Bard, Inc. will post 11.89 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be paid a dividend of $0.26 per share. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $1.04 dividend on an annualized basis and a yield of 0.31%. C.R. Bard’s dividend payout ratio (DPR) is currently 13.70%.
In other C.R. Bard news, insider Christopher S. Holland sold 38,242 shares of C.R. Bard stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $334.04, for a total transaction of $12,774,357.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Vice Chairman John H. Weiland sold 33,435 shares of C.R. Bard stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $333.31, for a total transaction of $11,144,219.85. Following the transaction, the insider now directly owns 76,331 shares in the company, valued at approximately $25,441,885.61. The disclosure for this sale can be found here. Insiders have sold a total of 191,593 shares of company stock valued at $62,655,513 in the last quarter. Company insiders own 0.80% of the company’s stock.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.